Product Description
a P2X3 receptor antagonist with high selectivity
Mechanisms of Action: P2X3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Refractory Chronic Cough|Unexplained Chronic Cough
Phase 1: Endometriosis|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03535168 | P2 |
Completed |
Refractory Chronic Cough|Unexplained Chronic Cough |
2019-09-25 |
34% |
| NCT03789890 | P1 |
Completed |
Endometriosis |
2019-03-04 |
28% |
| BAY 1902607 | P1 |
Completed |
Healthy Volunteers |
2018-05-03 |
28% |